1-13 of 13
origin trial
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk

Marie Pigeyre, Jennifer Sjaarda, Shihong Mao, Michael Chong, Sibylle Hess, Salim Yusuf, Hertzel Gerstein, Guillaume Paré
Journal: Diabetes Care
Diabetes Care 2019;42(9):1800–1808
https://doi.org/10.2337/dc18-2444
Published: 24 June 2019
View article titled, Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk
Open the PDF for Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk in another window
Includes: Supplementary data
Journal Articles

Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial

Tali Cukierman-Yaffe, Jackie Bosch, Hyejung Jung, Zubin Punthakee, Hertzel C. Gerstein
Journal: Diabetes Care
Diabetes Care 2019;42(1):142–147
https://doi.org/10.2337/dc18-0690
Published: 13 November 2018
View article titled, Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial
Open the PDF for Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial in another window
Includes: Supplementary data
Journal Articles

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial

Mario Luca Morieri, He Gao, Marie Pigeyre, Hetal S. Shah, Jennifer Sjaarda, Christine Mendonca, Timothy Hastings, Patinut Buranasupkajorn, Alison A. Motsinger-Reif, Daniel M. Rotroff, Ronald J. Sigal, Santica M. Marcovina, Peter Kraft, John B. Buse, Michael J. Wagner, Hertzel C. Gerstein, Josyf C. Mychaleckyj, Guillaume Parè, Alessandro Doria
Journal: Diabetes Care
Diabetes Care 2018;41(11):2404–2413
https://doi.org/10.2337/dc18-0709
Published: 27 September 2018
View article titled, Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial
Open the PDF for Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Growth Differentiation Factor 15 as a Novel Biomarker for Metformin

Hertzel C. Gerstein, Guillaume Pare, Sibylle Hess, Rebecca J. Ford, Jennifer Sjaarda, Kripa Raman, Matthew McQueen, ShunFu Lee, Heinz Haenel, Gregory R. Steinberg
Journal: Diabetes Care
Diabetes Care 2017;40(2):280–283
https://doi.org/10.2337/dc16-1682
Published: 14 December 2016
View article titled, Growth Differentiation Factor 15 as a Novel Biomarker for Metformin
Open the PDF for Growth Differentiation Factor 15 as a Novel Biomarker for Metformin in another window
Includes: Supplementary data
Journal Articles

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial

Hetal S. Shah, He Gao, Mario Luca Morieri, Jan Skupien, Skylar Marvel, Guillaume Paré, Gaia C. Mannino, Patinut Buranasupkajorn, Christine Mendonca, Timothy Hastings, Santica M. Marcovina, Ronald J. Sigal, Hertzel C. Gerstein, Michael J. Wagner, Alison A. Motsinger-Reif, John B. Buse, Peter Kraft, Josyf C. Mychaleckyj, Alessandro Doria
Journal: Diabetes Care
Diabetes Care 2016;39(11):1915–1924
https://doi.org/10.2337/dc16-0285
Published: 15 August 2016
View article titled, Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial
Open the PDF for Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

Oliver Schnell, Katharine Barnard, Richard Bergenstal, Emanuele Bosi, Satish Garg, Bruno Guerci, Thomas Haak, Irl B. Hirsch, Linong Ji, Sashank R. Joshi, Maarten Kamp, Lori Laffel, Chantal Mathieu, William H. Polonsky, Frank Snoek, Philip Home
Journal: Diabetes Care
Diabetes Care 2015;38(9):1627–1633
https://doi.org/10.2337/dc14-2919
Published: 10 August 2015
View article titled, Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research
Open the PDF for Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research in another window
Journal Articles

Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial

The ORIGIN Trial Investigators
Journal: Diabetes Care
Diabetes Care 2015;38(1):22–28
https://doi.org/10.2337/dc14-1329
Published: 28 October 2014
View article titled, Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial
Open the PDF for Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial in another window
Includes: Supplementary data
Journal Articles

Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366

Louise Bordeleau, Hertzel C. Gerstein
Journal: Diabetes Care
Diabetes Care 2014;37(10):e223
https://doi.org/10.2337/dc14-1567
Published: 10 September 2014
View article titled, Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366
Open the PDF for Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366 in another window
Journal Articles

Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial

The ORIGIN Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(10):2915–2922
https://doi.org/10.2337/dc12-2238
Published: 14 September 2013
View article titled, Characteristics Associated With Maintenance of Mean A1C &lt;6.5% in People With Dysglycemia in the ORIGIN Trial
Open the PDF for Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial in another window
Includes: Supplementary data
Journal Articles

Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922

Matthew C. Riddle, MD, Hertzel Gerstein, MD, for the ORIGIN Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(10):e181
https://doi.org/10.2337/dc13-1319
Published: 14 September 2013
View article titled, Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C &lt;6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922
Open the PDF for Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922 in another window
Journal Articles

Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922

Katherine Esposito, MD, PHD, Dario Giugliano, MD, PHD
Journal: Diabetes Care
Diabetes Care 2013;36(10):e180
https://doi.org/10.2337/dc13-1167
Published: 14 September 2013
View article titled, Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C &lt;6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922
Open the PDF for Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922 in another window
Journal Articles

Insulin as an Early Treatment for Type 2 Diabetes: ORIGIN or end of an old question?

Stefano Del Prato, MD, Cristina Bianchi, MD, PHD, Angela Dardano, MD, PHD, Roberto Miccoli, MD
Journal: Diabetes Care
Diabetes Care 2013;36(Supplement_2):S198–S204
https://doi.org/10.2337/dcS13-2019
Published: 17 July 2013
View article titled, Insulin as an Early Treatment for Type 2 Diabetes: <subtitle>ORIGIN or end of an old question?</subtitle>
Open the PDF for Insulin as an Early Treatment for Type 2 Diabetes: <subtitle>ORIGIN or end of an old question?</subtitle> in another window
Journal Articles

Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial

Ambady Ramachandran, MD, Matthew C. Riddle, MD, Conrad Kabali, PHD, Hertzel C. Gerstein, MD, on behalf of the ORIGIN Investigators
Journal: Diabetes Care
Diabetes Care 2012;35(4):749–753
https://doi.org/10.2337/dc11-1918
Published: 13 March 2012
View article titled, Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: <subtitle>An analysis of baseline data from the ORIGIN trial</subtitle>
Open the PDF for Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: <subtitle>An analysis of baseline data from the ORIGIN trial</subtitle> in another window
Includes: Supplementary data